Eone Diagnomics Genome Center Co.Ltd. announced a private placement of series 8 unregistered unguaranteed private convertible bonds for gross proceeds of KRW 10,000,000,000 on November 29, 2021. The transaction will involve participation from new investor, Korea Investment Hanwha Healthcare Private Equity Fund Co. Ltd for KRW 10,000,000,000. The bonds will mature on December 10, 2026. The bonds will be issued at par and carry no coupon rate and yield to maturity. The bonds are fully convertible into 2,807,411 common shares for 3.35% stake in the company at KRW 3,562 per share. The conversion period will be from December 10, 2022 to November 10, 2026. The subscription date is December 1, 2021 and the payment date is December 10, 2021. The transaction has been approved by the board of directors. The securities are subject to 1 year hold period.